(Mirikizumab)Biosimilar Reference Antibody-GS40438 新品

货号：GS40438

Mirikizumab is a humanized IgG4 monoclonal antibody that selectively targets the p19 subunit of interleukin‑23 (IL‑23), a key cytokine involved in the pathogenesis of several immune‑mediated inflammatory diseases. By binding to IL‑23p19, it prevents IL‑23 from interacting with its receptor, thereby inhibiting the differentiation and activation of Th17 cells and the production of downstream pro‑inflammatory cytokines (e.g., IL‑17, IL‑22). It is approved in multiple regions (including the US, EU, and Japan) for the treatment of moderately to severely active ulcerative colitis (UC) and is also under regulatory review for moderate‑to‑severe Crohn’s disease (CD). It is administered via subcutaneous injection.